NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for Thursday, March 20, 2025, before market open.
The company will host a conference call at 9:00 AM ET on the same day to discuss the results. Investors can access the call through a live webcast available on the company's investor relations website or through a dial-in option after registration. Questions can be submitted through the webcast portal or via email to NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS), un'azienda di tecnologia medica focalizzata sulle terapie di neuromodulazione per condizioni croniche e debilitanti, ha programmato l'annuncio dei risultati finanziari del Quarto Trimestre e dell'Anno Completo 2024 per giovedì 20 marzo 2025, prima dell'apertura del mercato.
L'azienda ospiterà una conferenza telefonica alle 9:00 AM ET lo stesso giorno per discutere i risultati. Gli investitori possono accedere alla chiamata tramite un webcast dal vivo disponibile sul sito web delle relazioni con gli investitori dell'azienda o tramite un'opzione di chiamata dopo registrazione. Le domande possono essere inviate attraverso il portale del webcast o via email a NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS), una empresa de tecnología médica centrada en terapias de neuromodulación para condiciones crónicas y debilitantes, ha programado el anuncio de sus resultados financieros del Cuarto Trimestre y del Año Completo 2024 para jueves, 20 de marzo de 2025, antes de la apertura del mercado.
La empresa llevará a cabo una llamada de conferencia a las 9:00 AM ET el mismo día para discutir los resultados. Los inversores pueden acceder a la llamada a través de una transmisión en vivo disponible en el sitio web de relaciones con inversores de la empresa o mediante una opción de llamada después de registrarse. Las preguntas se pueden enviar a través del portal de transmisión o por correo electrónico a NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS)는 만성 및 쇠약한 질환을 위한 신경 조절 치료에 중점을 둔 의료 기술 회사로, 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 3월 20일 목요일 시장 개장 전에 예정하고 있습니다.
회사는 같은 날 오전 9:00 ET에 결과를 논의하기 위한 전화 회의를 개최할 예정입니다. 투자자는 회사의 투자자 관계 웹사이트에서 제공되는 생중계 또는 등록 후 전화 접속 옵션을 통해 통화에 접근할 수 있습니다. 질문은 생중계 포털을 통해 또는 NRXS@lythampartners.com으로 이메일을 통해 제출할 수 있습니다.
NeurAxis (NYSE American: NRXS), une entreprise de technologie médicale axée sur les thérapies de neuromodulation pour des conditions chroniques et débilitantes, a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le jeudi 20 mars 2025, avant l'ouverture du marché.
L'entreprise organisera une conférence téléphonique à 9h00 ET le même jour pour discuter des résultats. Les investisseurs peuvent accéder à l'appel via un webcast en direct disponible sur le site des relations avec les investisseurs de l'entreprise ou via une option de connexion après inscription. Les questions peuvent être soumises par le biais du portail de webcast ou par e-mail à NRXS@lythampartners.com.
NeurAxis (NYSE American: NRXS), ein Medizintechnikunternehmen, das sich auf Neuromodulationstherapien für chronische und belastende Erkrankungen konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Donnerstag, den 20. März 2025, vor Markteröffnung angesetzt.
Das Unternehmen wird am selben Tag um 9:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über einen Live-Webcast, der auf der Website für Investor Relations des Unternehmens verfügbar ist, oder über eine Einwahloption nach Registrierung auf die Konferenz zugreifen. Fragen können über das Webcast-Portal oder per E-Mail an NRXS@lythampartners.com eingereicht werden.
- None.
- None.
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thursday, March 20, 2025, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Thursday, March 20, 2025, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/ztpz6rwm. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/ztpz6rwm.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis (NRXS) release its Q4 and Full Year 2024 earnings?
How can investors join the NeurAxis (NRXS) Q4 2024 earnings call?
Where can I find the replay of NeurAxis (NRXS) Q4 2024 earnings call?
How can investors submit questions during the NeurAxis (NRXS) earnings call?
